Comparative Pharmacology
Head-to-head clinical analysis: KESIMPTA versus KEVZARA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KESIMPTA versus KEVZARA.
KESIMPTA vs KEVZARA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KESIMPTA (ofatumumab) is a fully human anti-CD20 monoclonal antibody that selectively binds to the CD20 antigen on B lymphocytes, leading to B-cell lysis via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This results in depletion of circulating B cells, reducing inflammatory demyelination in multiple sclerosis.
Interleukin-6 (IL-6) receptor antagonist; sarilumab binds specifically to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signaling through gp130 and STAT3.
20 mg administered subcutaneously once monthly after a loading dose of 20 mg on Days 0, 7, and 14.
200 mg subcutaneously once weekly.
None Documented
None Documented
16 days (range 13–20 days) with linear pharmacokinetics; supports every 4-week dosing.
Terminal elimination half-life ~21-22 days, supporting subcutaneous dosing every 2 weeks.
Primarily degraded into small peptides and amino acids; not excreted renally or fecally as intact drug. Elimination pathways not fully characterized due to monoclonal antibody catabolism.
Primarily eliminated via reticuloendothelial system catabolism. No significant renal or biliary excretion; <1% excreted unchanged in urine or feces.
Category C
Category C
Monoclonal Antibody, Anti-CD20
Monoclonal Antibody, IL-6 Receptor Antagonist